Commitments and Contingencies - Additional Information (Details) $ in Thousands, £ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 GBP (£)
Other Commitments [Line Items]
Research and development expense	$ 83,105	$ 32,841
Alloy Therapeutics Llc [Member]
Other Commitments [Line Items]
Payment of annual license fees and program fees	100
Research and development expense	600	100
Alloy Therapeutics Llc [Member] \| Development Milestone [Member] \| First Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	1,800
Alloy Therapeutics Llc [Member] \| Development Milestone [Member] \| Second Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	3,100
Alloy Therapeutics Llc [Member] \| Commercial Milestone [Member] \| First Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	11,000
Alloy Therapeutics Llc [Member] \| Commercial Milestone [Member] \| Second Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	15,000
OmniAb, Inc [Member]
Other Commitments [Line Items]
Research and development expense	100	300
OmniAb, Inc [Member] \| Development Milestone [Member]
Other Commitments [Line Items]
Potential milestone payments due	12,200
IONTAS Limited [Member]
Other Commitments [Line Items]
Research and development expense	2,000	$ 2,100
IONTAS Limited [Member] \| Development Milestone [Member] \| First Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	3,900		£ 3.1
IONTAS Limited [Member] \| Development Milestone [Member] \| Second Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	3,100		2.5
IONTAS Limited [Member] \| Commercial Milestone [Member] \| First Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	$ 2,900		£ 2.3